Selling AAA in Europe
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences will distribute Endologix' PowerLink abdominal aortic aneurysm stent graft in Belgium, France, Germany and the UK. PowerLink received CE mark in 1999. A PMA is pending at FDA, and the firm expects approval during the second half of the year. Endologix plans to create a direct sales force for U.S. commercialization. Edwards recently abandoned its LifePath AAA program after unsuccessfully seeking a buyer (1"The Gray Sheet" April 12, 2004, In Brief)...
You may also be interested in...
Edwards scraps AAA program
Edwards Lifesciences' inability to find a buyer for its LifePath aortic aneurysm endovascular graft system will lead to termination of the program, the company says. The only firms with endovascular surgery sales forces capable of supporting LifePath already offer AAA grafts or are developing them, Edwards explains. The company announced its intention to exit the AAA business in December (1"The Gray Sheet" Dec. 15, 2003, p. 7). European sales will end in June. Edwards says it will complete patient follow-up for a U.S. study which closed enrollment in January...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.